Zelboraf 240 mg film-coated tablets
UC-0105/1401
Phase 2 small_molecule active
Quick answer
Zelboraf 240 mg film-coated tablets for Patients with metastatic or unresectable locally advanced malignancies harboring BRAF genomic alterations, the biological target of vemurafenib, and who are no more amenable to curative treatment is a Phase 2 program (small_molecule) at Cancer Prevention Pharma (Ireland) Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Cancer Prevention Pharma (Ireland) Limited
- Indication
- Patients with metastatic or unresectable locally advanced malignancies harboring BRAF genomic alterations, the biological target of vemurafenib, and who are no more amenable to curative treatment
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active